指南与共识膀胱癌与上尿路尿路上皮癌肾癌与肾肿瘤

AUA 2020/2025显微镜下血尿指南对尿路上皮癌与肾皮质肿瘤预测价值的批判性分析

Critical Analysis of the AUA 2020/2025 Microscopic Hematuria Guidelines to Predict Urothelial but Not Renal Cortical Neoplasms and Validation of the Individual Clinical Components in Risk Stratification for Urothelial Neoplasms but Not Renal Cortical Neoplasms.
指南 / 共识 · J Urol · 2025-11-20

该回顾性研究纳入4550例无症状显微镜下血尿患者,评估AUA 2025指南风险分层对尿路上皮癌和肾皮质肿瘤的预测效能。结果显示指南能有效分层尿路上皮癌风险,但对肾皮质肿瘤无显著预测价值;女性≥70岁尿路上皮癌发生率为2.2%,建议视为高危。

要点

  • AUA 2025指南可有效分层显微镜下血尿患者的尿路上皮癌风险,但对肾皮质肿瘤无预测价值。
  • 高危组尿路上皮癌发生率为3.8%,中危组0.8%,低危组0.2%。
  • 女性≥70岁尿路上皮癌发生率为2.2%,建议考虑列为高危。

核心结论

  • AUA 2025指南能有效将显微镜下血尿患者分层为尿路上皮癌风险组,但不能预测任何类型的肾皮质肿瘤。

研究设计与样本

  • 回顾性研究分析2010至2023年4550例无症状显微镜下血尿患者,均接受影像学和膀胱镜检查。

主要发现

  • 总体肿瘤发生率为3.1%,其中尿路上皮癌1.5%,肾皮质肿瘤1.6%(血管平滑肌脂肪瘤1.3%,非血管平滑肌脂肪瘤肾肿块0.35%)。
  • 高危组尿路上皮癌发生率为3.8%,中危组0.8%,低危组0.2%。
  • 各风险组间任何类型肾肿瘤的发生率无显著差异。
  • 年龄、男性、吸烟包年数和尿红细胞计数是尿路上皮癌的显著预测因素。
  • 仅男性和吸烟史可预测非血管平滑肌脂肪瘤肾肿瘤,血尿程度和吸烟包年数无预测作用。

关键数值与推荐

  • AUA 2025指南近期修订中,女性年龄≥60岁不再列为高危,但本研究中女性≥70岁膀胱癌发生率为2.2%。

临床怎么用

  • 临床可采用AUA 2025指南对显微镜下血尿患者进行尿路上皮癌风险分层。
  • 对肾皮质肿瘤的预测价值不足,提示需重新调整肾脏影像学检查的类型和目标。
  • 女性≥70岁可考虑视为尿路上皮癌高危人群。

局限性

  • 回顾性研究设计可能引入选择偏倚。
  • 未报告其他潜在局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the performance of the AUA 2025 guidelines stratification process in patients with microscopic hematuria (MH) to predict urothelial and renal cortical neoplasms and to assess the specific clinical components used in this stratification. MATERIALS AND METHODS: This retrospective study analyzed 4550 patients with asymptomatic MH, evaluated from 2010 to 2023 who underwent both imaging and cystoscopy. Patients were classified into risk groups based on the AUA 2025 guidelines to predict the presence of total neoplasms, specifically urothelial and renal cortical neoplasms and to validate the specific clinical components used in the guidelines. RESULTS: Among the 4550 patients, the overall neoplasm incidence was 3.1%, with urothelial neoplasms at 1.5% and renal cortical neoplasms at 1.6% (1.3% angiomyolipomas [AML] and 0.35% non-AML renal masses). High-risk patients had a higher incidence of urothelial malignancy (3.8%) compared with intermediate-risk and low-risk patients (0.8% and 0.2%, respectively), while the incidence of renal neoplasms of any type was not significantly different across risk groups. Significant predictors of urothelial malignancies included age, male gender, smoking pack years, and urinary red blood cells count, validating the AUA 2025 guidelines. However, only male gender and smoking history but not degree of hematuria or pack years of smoking predicted non-AML renal tumors. In the recent amendment, women were not classified as high risk based on age ≥60, but this study noted that women ≥70 had an incidence of bladder cancer at 2.2%. CONCLUSIONS: The AUA 2025 guidelines effectively stratify patients with MH into risk groups for urothelial cancer but not renal cortical neoplasms of any kind. Furthermore, the variables used in the construction of this model were also validated for urothelial cancers but not renal neoplasms. In this study, women older than 70 years have an incidence of urothelial cancer of 2.2%, suggesting that women older than 70 years should be considered high risk. The lack of predictive value for renal cortical neoplasms suggests areas for guideline realignment, specifically the type and goal of renal imaging.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Udedibia E, Solosky K, Macdonald EJ, et al. Critical Analysis of the AUA 2020/2025 Microscopic Hematuria Guidelines to Predict Urothelial but Not Renal Cortical Neoplasms and Validation of the Individual Clinical Components in Risk Stratification for Urothelial Neoplasms but Not Renal Cortical Neoplasms. J Urol. 2025. PMID: 41264791. doi:10.1097/JU.0000000000004854

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。